



**Food and Drug Administration
OFFICE OF CRIMINAL INVESTIGATIONS
REPORT OF INVESTIGATION**

REPORTING OFFICE: San Francisco Resident Office

DOCUMENT NUMBER: 266925

CASE NUMBER: 2010-SFC-735-0280-J

RELATED CASE NUMBER: (b) (7)(E)

TYPE OF CASE: 735.100, DIETARY SUPPLEMENTS - CDER

CASE TITLE: PRIMORDIAL PERFORMANCE

CASE AGENT: (b) (7)(F)

INVESTIGATION MADE AT: Portland, OR

INVESTIGATION MADE BY: SA (b) (7)(F)

REPORTING PERIOD: **FROM:** 06/01/2018 **TO:** 08/29/2018

STATUS OF CASE: Continued

SYNOPSIS: Review of evidence (b) (7)(E)

RESTRICTED INFORMATION

This report is furnished on an official need-to-know basis and must be protected from dissemination which might compromise the best interests of the Food and Drug Administration, Office of Criminal Investigations. This report shall not be released in response to a Freedom of Information Act or Privacy Act request or disseminated to other parties without prior consultation with the FDA Office of Criminal Investigations.

UNAUTHORIZED RELEASE MAY RESULT IN CRIMINAL PROSECUTION

REPORT SUBMITTED BY: Electronically submitted by (b) (7)(F) _____ **DATE:** 08/29/2018
(b) (7)(F), SPECIAL AGENT

REPORT APPROVED BY: Electronically approved by STEPHEN JACKSON _____ **DATE:** 08/30/2018
STEPHEN JACKSON, RESIDENT AGENT IN CHARGE

DISTRIBUTION: ORIG: SFC

1. INTRODUCTION:

This case originated after the February 8, 2010, receipt of information from the United States Anti-Doping Agency (USADA) about an email solicitation from PRIMORDIAL PERFORMANCE on the sale of a new product called Superdrone. The email indicates that PRIMORDIAL PERFORMANCE's Superdrone is a "Superdrol-clone" and contains the designer anabolic steroid methyltestosterone. Superdrol (aka methyltestosterone, aka methasteron) is a designer anabolic steroid (b) (7)(E)

(b) (7)(E)

Reference is made to the Report of Investigation for the period March 3, 2018 through May 31, 2018.

2. DETAILS OF INVESTIGATION:

(b) (7)(E)

(b) (7)(E), (b) (7)(F)

On August 21, 2018 SA (b) (7)(F) participated in a conference call with OCC Attorney Smith and Investigative Analyst (b) (7)(F) regarding final disposition of evidence in this case. On the same date OCC Attorney Smith sent an email to Public Defender Graham Archer to determine if he represented ERIC POTRATZ for purposes of final disposition of the evidence.

3. JUDICIAL ACTION:

None.

4. DISPOSITION OF EVIDENCE, CONTRABAND, AND PERSONAL PROPERTY:

None.

5. STATUS OF INVESTIGATION:

Continued.

6. SUSPECTS/DEFENDANTS/OTHER:

PRIMORDIAL PERFORMANCE

ERIC POTRATZ

(b) (6), (b) (7)(C)

WWW.PRIMORDIALPERFORMANCE.COM

(b) (6), (b) (7)(C)

(b) (6), (b) (7)(C)

[Redacted]

7. ATTACHMENTS:

None.